Availability of data and materials

Availability of data and materials

Submission of a manuscript to Cancer Biome and Targeted Therapy (CBTT) implies that all materials, data, and protocols described in the article will be made readily available, without restriction, to any qualified researcher for non-commercial research purposes. This openness is essential to ensure the reproducibility, transparency, and credibility of published research.

Data Availability Statement

If no data were generated or analyzed during the current study, authors should include the following statement in their manuscript:
“No datasets were generated or analyzed during the current study.”

Data Deposition and Sharing Requirements

For specific data types where community standards exist, authors are required to deposit data in publicly accessible repositories before or at the time of submission. Examples include:

  • Genomic, transcriptomic, and proteomic data: Submit to repositories such as NCBI’s Gene Expression Omnibus (GEO), EMBL-EBI’s ArrayExpress, or equivalent.
  • Nucleotide and protein sequences: Submit to GenBank, EMBL, or DDBJ databases.
  • Microarray data: Must comply with MIAME (Minimum Information About a Microarray Experiment) standards.

Authors must provide accession numbers or persistent identifiers for deposited datasets within the manuscript text.

Clinical Data and Participant Privacy

For manuscripts involving clinical or patient-derived data, authors must uphold ethical and legal responsibilities to protect participant privacy, including:

  • Obtaining informed consent for data sharing and publication at recruitment whenever possible.
  • Clearly explaining how participant confidentiality and data protection were ensured.
  • Demonstrating compliance with applicable regulations such as GDPR, HIPAA, and institutional review board (IRB) or ethics committee approvals.

If informed consent cannot be obtained, authors must provide compelling justification that the publication does not compromise anonymity or violate laws.

Cell Line Authentication

Manuscripts using human or animal cell lines must provide information to support validity and reproducibility, including: Source of the cell line (provider name and acquisition date). Authentication is highly recommended.

Authors are encouraged to follow guidelines from the International Cell Line Authentication Committee (ICLAC) and verify cell line identity using resources such as the NCBI BioSample database (https://www.ncbi.nlm.nih.gov/biosample/) and Cellosaurus (https://www.cellosaurus.org). Manuscripts involving misidentified, unvalidated, or contaminated cell lines may be rejected or retracted if findings rely heavily on such lines.

Gene Nomenclature

Authors must use standardized gene nomenclature throughout the manuscript. For human genes, names and symbols should conform to the guidelines of the HUGO Gene Nomenclature Committee (HGNC). Authors should verify gene names using the HGNC database to ensure accuracy.

Statistical Reporting Standards

Manuscripts must include a clear and complete description of all statistical methods applied, including:

  • Specific statistical tests used.
  • Measures of variance and uncertainty (e.g., confidence intervals, p-values).
  • Justification for the appropriateness of statistical methods.

The journal recommends adherence to the SAMPL (Statistical Analyses and Methods in the Published Literature) guidelines for robust and transparent statistical reporting.

Last updated: August 2025